Search

Your search keyword '"Vieira, Rafael José"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Vieira, Rafael José" Remove constraint Author: "Vieira, Rafael José" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
142 results on '"Vieira, Rafael José"'

Search Results

1. Impact of Allergic Rhinitis Control on Work Productivity and Costs: A Real-World Data MASK-air Study

2. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

4. Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study

6. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

7. Intranasal Versus Oral Treatments for Allergic Rhinitis: A Systematic Review With Meta-Analysis

9. Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

10. Cutoff Values of MASK-air Patient-Reported Outcome Measures

12. Embedding patients' values and preferences in guideline development for allergic diseases: The case study of Allergic Rhinitis and its Impact on Asthma 2024

13. Academic Productivity of Young People With Allergic Rhinitis: A MASK-air Study

14. Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis.

15. Artificial Intelligence–Supported Development of Health Guideline Questions.

17. Regional, sex, and age inequities in asthma hospital admissions in Spain and Portugal

18. Patients' values and preferences for health states in allergic rhinitis—An artificial intelligence supported systematic review

19. Poor rhinitis and asthma control is associated with decreased health-related quality-of-life and utilities: A MASK-air study

20. Poor rhinitis and asthma control is associated with decreased health-related quality-of-life and utilities: A MASK-air study

21. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

22. Impact of Uncontrolled Symptoms on the Health‐Related Quality of Life (EQ‐5D‐5L) of Patients With Allergic Rhinitis: A MASK‐air Study.

24. Intranasal antihistamines and corticosteroids in the treatment of allergic rhinitis: a systematic review and meta-analysis protocol

25. Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

26. Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices

27. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach.

28. Consistent trajectories of rhinitis control and treatment in 16,177 weeks : the MASK-air® longitudinal study

29. Patient-centered digital biomarkers for allergic respiratory diseases and asthma:The ARIA-EAACI approach – ARIA-EAACI Task Force Report

30. Patient‐centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA‐EAACI approach

31. Burden of infectious disease studies in Europe and the United Kingdom:a review of methodological design choices

32. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

33. Development and validation of an electronic daily control score for asthma (e-DASTHMA):a real-world direct patient data study

34. Consistent trajectories of rhinitis control and treatment in 16,177 weeks

35. MASK‐air® direct patient data support the ARIA‐MeDALL hypothesis on allergic phenotypes.

36. Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices

37. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

38. Cutoff Values of MASK-air Patient-Reported Outcome Measures

39. The ARIA-MASK-air® approach

40. A study using MASK-air® real-world data

41. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK‐air® longitudinal study

42. Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

45. Comparison of rhinitis treatments using MASK ‐air® data and considering the minimal important difference

46. Behavioural patterns in allergic rhinitis medication in Europe : a study using 28 MASK-air® real-world data

47. Results of a Bayesian mixed-effects model

48. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference

49. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air real-world data.

50. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.

Catalog

Books, media, physical & digital resources